ArticleInternational journal of medical sciences2014
Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
Article in International journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.Aging clinical and experimental research · 2025Pooled it
- The Real-World Safety Profile of Haloperidol: A Comprehensive Pharmacovigilance Analysis Using the Large-Scale FAERS Database.CNS neuroscience & therapeutics · 2026Article
- Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Spectrum and prognosis of CAR-T-related endocrine toxicity: glucose/calcium dysregulation, pituitary axis disorders, and overlap with CRS.Frontiers in medicine · 2026Article
- Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learning.Frontiers in drug safety and regulation · 2026Article
- Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study.Frontiers in pharmacology · 2026Article
- Synergistic toxicity and clinical prioritization of docetaxel combined with nintedanib for non-small cell lung cancer: a real-world safety analysis using the FAERS database.Frontiers in oncology · 2026Article
- Signal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.Human vaccines & immunotherapeutics · 2025Article
- Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study.EClinicalMedicine · 2025Article
- A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.Scientific reports · 2025Article
- Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.Therapeutic innovation & regulatory science · 2025Article
- The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study.BMC pharmacology & toxicology · 2025Article
- A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database.Scientific reports · 2025Article
- Unveiling the differences: infection disorders associated with tumor necrosis factor α inhibitors in pediatric patients-a pharmacovigilance study (2004-2023).European journal of pediatrics · 2025Article
- Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.Archives of dermatological research · 2025Article
- Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system.Scientific reports · 2025Article
- The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database.Frontiers in pharmacology · 2025Article
- Adverse events associated with ustekinumab in Crohn's disease treatment: an analysis based on the FAERS database.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesData mining algorithms have been developed for the quantitative detection of drug-associated adverse events (signals) from a large database on spontaneously reported adverse events. In the present study, the commonality of signals detected by 4 commonly used data mining algorithms was examined.
methodsA total of 2,231,029 reports were retrieved from the public release of the US Food and Drug Administration Adverse Event Reporting System database between 2004 and 2009. The deletion of duplicated submissions and revision of arbitrary drug names resulted in a reduction in the number of reports to 1,644,220. Associations with adverse events were analyzed for 16 unrelated drugs, using the proportional reporting ratio (PRR), reporting odds ratio (ROR), information component (IC), and empirical Bayes geometric mean (EBGM).
resultsAll EBGM-based signals were included in the PRR-based signals as well as IC- or ROR-based ones, and PRR- and IC-based signals were included in ROR-based ones. The PRR scores of PRR-based signals were significantly larger for 15 of 16 drugs when adverse events were also detected as signals by the EBGM method, as were the IC scores of IC-based signals for all drugs; however, no such effect was observed in the ROR scores of ROR-based signals.
conclusionsThe EBGM method was the most conservative among the 4 methods examined, which suggested its better suitability for pharmacoepidemiological studies. Further examinations should be performed on the reproducibility of clinical observations, especially for EBGM-based signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.